The Italian Competition Authority fines a leading pharmaceutical company € 10.6 M for abusing its dominant position (Pfizer)

The Italian Competition Authority (AGCM) has fined the Pfizer group, a multinational company in the pharmaceutical sector, a total of 10.6 million euro for abusing its dominant position in the market for commercializing glaucoma medicines based on the active ingredient latanoprost. The Pfizer group operated a complex strategy designed to exclude and obstruct the entry of generic drugs into the market [1]. This complex and exclusionary strategy consisted into: 1. Asking the European Patent Office (EPO) for a divisional patent in 2002, which was obtained in 2009. The divisional patent was asked 13 years after getting the principal patent and in a period when two generic drugs based on the same

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • DG COMP (Brussels)

Quotation

Andrea Usai, The Italian Competition Authority fines a leading pharmaceutical company € 10.6 M for abusing its dominant position (Pfizer), 11 January 2012, e-Competitions January 2012, Art. N° 44141

Visites 598

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues